TARS - Company ID 0001819790
The table below shows Tarsus Pharmaceuticals, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $183.64M | $94.82M | $224.95M | $71.66M | $171.33M | $168.13M |
| Short-term investments | $233.63M | $196.56M | $2.50M | $145.37M | $483.00K | - |
| Receivables | $85.06M | $46.76M | $16.62M | - | - | - |
| Inventory | $4.37M | $2.62M | $3.11M | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $522.78M |
| $356.70M |
| $256.13M |
| $225.38M |
| $175.95M |
| $170.66M |
| Property, plant & equipment | $11.66M | $2.31M | $1.47M | $957.00K | $755.00K | $548.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $562.16M | $376.99M | $265.49M | $227.86M | $178.91M | $171.97M |
| Accounts payable | $16.39M | - | - | - | - | - |
| Total current liabilities | $135.69M | $80.61M | $36.94M | $15.43M | $11.48M | $5.39M |
| Long-term debt | $72.44M | $71.84M | $29.82M | $19.43M | - | - |
| Total liabilities | $218.73M | $152.46M | $68.50M | $34.96M | $12.18M | $5.99M |
| Retained earnings | -$426.63M | -$360.21M | -$244.66M | -$108.76M | -$46.67M | -$32.84M |
| Total equity | $343.43M | $224.53M | $196.99M | $192.90M | $166.73M | $165.98M |